CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)

Mian, Michael; Marcheselli, Luigi; Luminari, Stefano; Federico, M.; Sarris, Andreas H.; Rossi, Andrea; Frontani, Marina; Devizzi, Liliana; Gianni, Alessandro M.; Busetto, M; Berti, Emilio; Martinelli, Giovanni; Tsang, Richard W.; Ferreri, Andrés J.M.; Pinotti, Graziella; Pogliani, Enrico Maria; Zucca, Emanuele; Cortelazzo, Sergio

doi:10.1007/s00277-010-1083-1

Cited by 26 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This led to the proposal of lymphoma-specific prognostic indices, the follicular lymphoma international prognostic index (FLIPI and FLIPI2), 6,7 the mantle cell lymphoma international prognostic index (MIPI), 8,9 and others for less common conditions. 10,11 Marginal zone lymphomas (MZLs) represent a heterogeneous subgroup, classified as extranodal, splenic, and nodal. Extranodal cases, also termed mucosa-associated lymphoid tissue (MALT), account for ;70% of MZLs.…”

Section: Introductionmentioning

confidence: 99%

A MALT lymphoma prognostic index

Thiéblemont

Cascione

Conconi

et al. 2017

Blood

Self Cite

160

124

View full text Add to dashboard Cite

There are no widely accepted prognostic indices for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). This study aimed to develop and validate a specific prognostic tool to personalize and optimize lymphoma treatment of patients with MALT lymphoma. A prognostic index was built by Cox regression (stepwise selection) using data from 401 patients enrolled in the international randomized IELSG-19 trial (NCT 00210353). A validation set, including 633 patients, was obtained by merging three independent cohorts of MALT lymphoma patients. The three individual features maintaining the greatest prognostic significance for event-free survival (EFS, the main endpoint of the IELSG-19 trial) were age ≥70 years (HR 1.72, 95% CI 1.26-2.33), Ann Arbor stage III or IV (HR 1.79, 95% CI 1.35-2.38), and elevated LDH level (HR 1.87, 95% CI 1.27-2.77). The prognostic index (MALT-IPI) constructed using these three parameters identified three groups: low, intermediate and high risk (corresponding to the presence of 0, 1 or ≥2 of these factors, respectively). The 5-year EFS rates in the low, intermediate and high risk groups were 70%, 56% and 29%, respectively. The MALT-IPI also significantly discriminated between patients with different progression-free, overall and cause-specific survival. The prognostic utility was retained in gastric and non-gastric lymphomas, in each treatment arm (chlorambucil, rituximab, rituximab plus chlorambucil), and was confirmed in the validation set. The new index, MALT-IPI, is a simple, accessible and effective tool to identify MALT lymphoma patients at risk of poor outcomes. It may help define appropriate treatment approaches for individual patients

show abstract

Section: Introductionmentioning

confidence: 99%

A MALT lymphoma prognostic index

Thiéblemont

Cascione

Conconi

et al. 2017

Blood

Self Cite

160

124

View full text Add to dashboard Cite

show abstract

“…[10][11][12] Thus, the early identification of patients who are likely to progress remains a challenge, especially for those cases with indolent histology (primary cutaneous marginal zone B-cell lymphoma and primary cutaneous centrofollicular lymphoma). 10,13,14 MicroRNAs (miRNAs) have recently been identified as potential markers for diagnosis and prognosis in various solid and hematolymphoid neoplasms. 15 miRNAs are small single-stranded, non-coding RNA molecules, about 22 nucleotides long, that regulate gene expression.…”

mentioning

confidence: 99%

MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma

et al. 2013

View full text Add to dashboard Cite

Indolent primary cutaneous B-cell lymphoma is a group of malignant lymphomas comprising marginal zone B-cell lymphoma and centrofollicular B-cell lymphoma. Relapse rate of these tumors is close to 40%, and identifying those patients who are likely to progress remains a challenge. The aim of this study was to characterize the microRNA (miRNA) expression profile of a series of primary cutaneous B-cell lymphomas and correlate with histological and clinical findings. We studied a series of 68 patients with primary cutaneous B-cell lymphomas (30 cutaneous marginal-zone B-cell lymphomas and 38 primary cutaneous centrofollicular lymphomas). A set of 11 miRNAs associated with the differentiation stage of B cells was quantified by realtime PCR, using RNA extracted from formalin-fixed, paraffin-embedded tissue diagnostic samples. Relevant clinical variables were retrieved in a subset of 57 patients (28 cutaneous marginal zone B-cell lymphomas and 29 primary cutaneous centrofollicular lymphomas). miR-150 was upregulated in cutaneous marginal zone B-cell lymphomas relative to primary cutaneous centrofollicular lymphoma samples (false discovery rate o0.05). miR-155 and miR-150 expression levels were associated with progression-free survival in a univariate Cox regression analysis (Po0.1). After stratification by histological subtype, low-expression levels of miR-155 and miR-150 were both associated with shorter progression-free survival only in primary cutaneous marginal zone B-cell lymphomas cases (log-rank test, Po0.05). In summary, miRNA expression analysis can be used as a tool for diagnosis and outcome prognosis in indolent primary cutaneous B-cell lymphoma.

show abstract

“… Clinical parameters: sex, nodular aspect, number of lesions treated (1 or ≥2), CLIPI score, larger diameter, lesion previously treated or not, prior systemic treatment or prior topic corticosteroids application. Biological/histopathological parameters such as histological type, CD20 > or ≤ 57%, Ki67 > or ≤ 57%, Bcl2/Bcl6 positivity (yes or no), LDH and β2‐microglobulin were studied. …”

Section: Methodsmentioning

confidence: 99%